Get started
Author

Delphine Argo-Leignel

Observed names: D. Argo Leignel, D. Argo-Leignel, Delphine Argo Leignel
ORCID: 0009-0009-8478-1329
Observed ORCID: 0009-0009-8478-1329
OpenAlex ID: A5090962166
Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial
2025 · Thomas Brion, Robabeh Ghodssighassemabadi, et al. · Radiotherapy and Oncology · 19
231O Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial
2024 · S. Rivera, R. Ghodssighassemabadi, et al. · Annals of Oncology · 15
PDF
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma
2021 · Nicolas Giraud, Olivier Saut, et al. · Cancers · 14
PDF
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
2026 · Sofia Rivera, Robabeh Ghodssighassemabadi, et al. · The Lancet · 11
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial
2023 · Véronique Vendrely, Philippe Ronchin, et al. · Radiotherapy and Oncology · 10
PDF
OC-0758 HypoG01:UNICANCER phase 3 trial of locoregional hypo vs normo fractionated RT in early breast cancer
2023 · S. Rivera, E. Karamouza, et al. · Radiotherapy and Oncology · 10
Local control assessment following SABR for lung metastases of colorectal cancer: A multicenter retrospective analysis
2025 · Robin Morcet-Delattre, Loïg Duvergé, et al. · Radiotherapy and Oncology · 8
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial
2025 · Thomas Brion, Mamadou Balde, et al. · Radiotherapy and Oncology · 5
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
2023 · Anouchka Modesto, David Tougeron, et al. · BMC Cancer · 4
PDF
121MO Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial
2021 · S. Rivera, T. Brion, et al. · Annals of Oncology · 4
Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer
2025 · Anouchka Modesto, Sophie Gibert, et al. · International Journal of Cancer · 2
PDF
Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).
2019 · Thomas Aparicio, Philippe Ronchin, et al. · Journal of Clinical Oncology · 2
Abstract PO5-21-03: Cosmetic assessment in the UNICANCER HypoG-01 trial: a deep learning approach
2024 · Alexandre Cafaro, Amandine Ruffier, et al. · Cancer Research · 1
P1.124: Treatment Patterns and Outcomes in Elderly Patients With Resected Stage IIIN2 NSCLC a Subgroup Analysis of the Lung ART Trial
2026 · M. Frelaut, N. Cozic, et al. · Journal of Thoracic Oncology
3554 Patterns of thyroid dysfunction after breast cancer treatment: results from the HypoG-01 phase III trial
2026 · Lisa Ciaptacz, Youssef Ghannam, et al. · Radiotherapy and Oncology
3964 Cost-effectiveness of locoregional hypofractionated RT in early breast cancer: evaluation alongside the HypoG-01 phase 3 Unicancer trial
2025 · Aldéric M. Fraslin, Alexandre Lolivier, et al. · Radiotherapy and Oncology
Abstract PO5-19-10: First oncological outcomes of HypoG-01: a UNICANCER phase III trial comparing loco-regional hypo vs normo fractionated radiation therapy in early breast cancer patients
2024 · Sofia Rivera, Eleni Karamouza, et al. · Cancer Research
1936: A dosimetric parameter to improve local control on colorectal cancer lung metastasis treated by SABR
2024 · Robin Morcet-Delattre, Joël Castelli, et al. · Radiotherapy and Oncology
Recherche clinique au sein des centres hospitaliers généraux en France, forces et faiblesses
2023 · D. Argo-Leignel, P. Bouju, et al. · Cancer/Radiothérapie
PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904)
2021 · V. Vendrely, P. Ronchin, et al. · Radiotherapy and Oncology
Post-Operative Radiotherapy (PORT) Versus No PORT in Patients With Completely Resected Non-Small Cell Lung Cancer and Proven Mediastinal N2 Involvement: An Open Label Randomised Phase 3 Superiority Trial (Lung ART (IFCT-0503, UK NCRI, SAKK))
2021 · Cecile Le Pechoux, Nicolas Pourel, et al. · SSRN Electronic Journal
Apport de la radiomique sur IRM pour prédire la réponse à 2 ans après chimioradiothérapie des cancers du canal anal localement évolués
2020 · N. Giraud, T. Aparicio, et al. · Cancer/Radiothérapie
Works count: 22
Citation count: 105
H-index: 7
I10-index: 6
Year
Topic
Type